New York State Teachers Retirement System lessened its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 3.0% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 217,934 shares of the medical instruments supplier's stock after selling 6,778 shares during the quarter. New York State Teachers Retirement System owned approximately 0.08% of Becton, Dickinson and Company worth $49,920,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BDX. Vanguard Group Inc. increased its stake in shares of Becton, Dickinson and Company by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 26,743,052 shares of the medical instruments supplier's stock worth $6,067,196,000 after acquiring an additional 184,288 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its position in Becton, Dickinson and Company by 36.1% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier's stock worth $2,751,187,000 after purchasing an additional 3,219,317 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Becton, Dickinson and Company by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 6,351,537 shares of the medical instruments supplier's stock worth $1,437,161,000 after purchasing an additional 66,024 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of Becton, Dickinson and Company by 15.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 6,175,899 shares of the medical instruments supplier's stock valued at $1,401,126,000 after buying an additional 810,345 shares during the last quarter. Finally, First Eagle Investment Management LLC grew its stake in shares of Becton, Dickinson and Company by 31.4% in the 4th quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier's stock valued at $1,004,132,000 after buying an additional 1,057,879 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.
Insider Buying and Selling at Becton, Dickinson and Company
In other news, EVP Michael David Garrison sold 479 shares of the stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the sale, the executive vice president owned 4,887 shares in the company, valued at approximately $964,107.36. This represents a 8.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP David Shan sold 1,166 shares of Becton, Dickinson and Company stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the transaction, the executive vice president directly owned 4,575 shares of the company's stock, valued at $783,194.25. This represents a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.36% of the stock is currently owned by insiders.
Becton, Dickinson and Company Stock Performance
Shares of BDX stock traded down $0.62 during mid-day trading on Wednesday, reaching $177.05. The stock had a trading volume of 3,277,445 shares, compared to its average volume of 2,055,838. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The firm has a market cap of $50.74 billion, a PE ratio of 33.79, a P/E/G ratio of 1.34 and a beta of 0.25. The firm's 50 day simple moving average is $175.59 and its 200 day simple moving average is $208.71. The company has a quick ratio of 0.64, a current ratio of 1.13 and a debt-to-equity ratio of 0.70.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, beating analysts' consensus estimates of $3.28 by $0.07. The business had revenue of $5.27 billion for the quarter, compared to analysts' expectations of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The firm's revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.17 earnings per share. On average, analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.
Becton, Dickinson and Company Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Monday, June 30th. Shareholders of record on Monday, June 9th were issued a dividend of $1.04 per share. The ex-dividend date of this dividend was Monday, June 9th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.35%. Becton, Dickinson and Company's payout ratio is presently 79.39%.
Analyst Upgrades and Downgrades
Several research analysts have recently commented on the stock. Stifel Nicolaus dropped their price target on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. William Blair cut Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research report on Thursday, May 1st. Wall Street Zen lowered Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. Bank of America downgraded Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 price objective on the stock. in a research note on Thursday, May 1st. Finally, Barclays decreased their target price on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research report on Tuesday, June 3rd. Eight equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of "Hold" and a consensus price target of $219.22.
Read Our Latest Stock Analysis on BDX
Becton, Dickinson and Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Read More
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
